Gedeon Richter (Gideon Richter)

Gedeon Richter (Russian Gideon Richter) is a Hungarian pharmaceutical company, the largest manufacturer of drugs in Eastern Europe. As of April 2024, the company's staff is 12,842 people, about 1,400 of whom work in Russia.

Performance indicators

2023: Market capitalization - €4.3 billion

By the end of 2023, Gedeon Richter's market capitalization was 4.3 billion euro (4.7 billion), US dollars and the company's consolidated sales amounted to 2.1 billion euros ($2.3 billion). USA

Business in Russia

Main article: Gideon Richter Rus

As of 2018, sales of Gideon Richter in Russia account for about 23% of total sales in the countries where the company operates. According to IMS Health, it is one of the top 10 foreign pharmaceutical companies operating in the Russian Federation.

History

2024

Discovery of biopharmaceutical cGMP production

On September 13, 2024, in the city of Bovenau (Germany), the opening of the biopharmaceutical cGMP manufactured by Richter BioLogics GmbH & Co KG, a division of Gedeon Richter for the production of microbiological drugs, took place.

The opening was attended by guests from local authorities and the scientific community, as well as business partners and employees of Richter BioLogics and Gedeon Richter. The event was attended by: Daniel Gunter, Minister-President of Schleswig-Holstein, Daniel Ambrock, Mayor of Bovenau, as well as representatives of Gedeon Richter: Eric Bogsch, Chairman Emeritus, Dale Martin, Member of the Supervisory Board, Dr. Eric Bogsch, Head of Biotech Business, Dr. Kai Polmeyer, CEO, and Johannes Salzbrunn, Operations. Richter Biologics.

Шаблон:Quote 'author = said Kai Polmeyer, CEO of Richter BioLogics.

The cGMP compliant plant is equipped with advanced equipment for clinical and large-scale commercial production and market delivery of protein and plasmid DNA products. The multifunctional enterprise increases the total production area to about 10,000 square meters. Production lines with capacities of 300 and 1500 liters provide additional flexibility due to the possibility of simultaneous production of various products with a volume of up to 120 batches per year. In addition, additional space is provided for further expansion of production. The complex also includes large laboratories for analytical research, storage facilities and technical facilities to optimize the flow of people and materials. By the end of 2024, the number of highly qualified local employees will double and exceed 400 people.

Шаблон:Quote 'author = noted Eric Bogsch, head of biotech business at Gedeon Richter.

BCI Pharma Acquisition

Gedeon Richter has announced the purchase of Belgian the manufacturer BCI Pharma , a private biotechnology research company that develops in different areas of women's health. The deal is valued euro at 12 million, payable over several years, as certain results are achieved. This Zdrav.Expert became known on June 24, 2024. More. here

Acquisition of a portion of Mithra Pharmaceuticals assets

Gedeon Richter announced the completion of negotiations with Mithra Pharmaceuticals SA to acquire part of the company's assets, as well as its Belgian subsidiary Mithra Recherche et Développement SA (Mithra R&D). The transaction involves the purchase of a 100% stake in Estetra SRL ("Aesetra") and Neuralis SA ("Neuralis"), as well as certain assets and licenses of Mithra R & D. The value of the transaction is estimated at 175 million euros, including inherited debt in net terms. Gedeon Richter announced this on June 17, 2024. Read more here.

Agreement with Helm AG to buy 50% stake in Richter-Helm BioTec and 30% stake in Richter-Helm BioLogics

Gedeon Richter has signed an agreement with German stock corporation HELM AG to buy a 50% stake in Richter-Helm BioTec (RHT) and a 30% stake in Richter-Helm BioLogics (RHB), making Gedeon Richter the 100% owner of both companies. This was announced to Zdrav.Expert on March 14, 2024 by representatives of Gedeon Richter.

𝓲

Gedeon Richter

Under the terms of the agreement, Gedeon Richter will pay €40.6 million for HELM's stake in Richter-Helm BioLogics and €71.8 million for its stake in Richter-Helm BioTec. Stakes in both companies are payable at the closing of the transaction until approval for the merger is obtained from the antimonopoly authorities of Germany and Hungary and other terms of the agreement are fulfilled. In addition to €71.8 million, Gedeon Richter will transfer additional performance payments to Richter-Helm BioTec during 2025-2029.

Richter-Helm BioTec is the owner of the biosimilar teriparatide and has numerous licensing partners worldwide, including pharmaceutical companies such as STADA, Daewon, Mochida and Gedeon Richter itself. The Terrosa (teriparatide) brand as of March 2024 is a key product of Gedeon Richter's biotech business unit, with sales of the drug totaling €56.8 million in 2023. Total sales of teriparatide worldwide by all Richter-Helm BioTec licensees reached nearly €125 million in 2023.

In turn, Richter-Helm BioTec is a microbiological contract company headquartered in northern Germany. It has three production sites with more than 300 employees. The company's annual income is about 60 million euros. RHB is expected to complete a major investment deal worth around €100m in 2024 to expand production and develop the range of services for pharmaceutical companies.

The deal consolidates Gedeon Richter's ownership and control of German biological assets and will further develop the biotech business unit. With RHB already majority owned by Gedeon Richter, RHB's integration into the biotech division is expected to succeed.

"Gedeon Richter's German assets and biotech capabilities in Hungary will create a powerful biotech platform to offer even better services to our customers and partners. This will provide long-term development for our company, "said Eric Bogsch, director of biotech at Gedeon Richter.

Geography of presence

According to information for March 2024, Gedeon Richter is present in Western Europe, China, Latin America and Australia.

Partnership with Formycon

Gedeon Richter has become a strategic investor in Formycon. Gedeon Richter announced this on February 5, 2024. Read more here.

2023: Acquisition of 100% stake in Giskit MD B.V.

Gedeon Richter and IQ Medical Ventures B.V. announced a share purchase agreement for Giskit MD B.V., which is a subsidiary of IQ Medical Ventures B.V. Giskit MD B.V. will be transferred to Gedeon Richter under the stock 100% agreement. This became known on July 25, 2023. Read more here.

2018

Production of about 100 generic and original drugs

As of 2018, Gedeon Richter produced about 100 generic and original drugs in more than 170 forms.

Aktivs

The company has expertise in many therapeutic areas. However, special attention is paid to research in the field of the central nervous system and female reproductive health.

The company has six own plants in its assets for 2018, one of which was opened in Yegoryevsk (Russia) in 1998. The staff of the company at that time was about 10 thousand people in the world, 1,500 of whom worked in Russia.